哮喘患者从干粉吸入器转换为压力定量吸入器的真实世界有效性
韩国单中心历史性队列研究显示,85例坚持换用pMDI的哮喘患者,换用后无急性发作比例提高(平均差0.129,95%CI 0.038-0.220),风险域控制(RDAC)达75.3% vs 57.7%(P=0.001),总体控制(OAC)为57.7% vs 45.9%(P=0.021)。117例换用固定剂量复方pMDI者中,76.1%(95%CI 69.0-100.0%)在6个月内坚持换药。
要点
- 换用pMDI并坚持可减少哮喘急性发作、改善控制。
- 换药后6个月坚持率约76.1%,多数患者可维持。
- 真实世界证据支持吸入装置转换的可行性。
核心结论
- 换用pMDI并坚持用药与哮喘急性发作减少和控制改善相关。
研究设计与样本
- 韩国Ajou大学医院患者记录的历史性队列研究。
- 共117例换用pMDI,其中85例坚持1年纳入有效性分析。
主要发现
- 换用后无急性发作比例平均差0.129(95%CI 0.038-0.220)。
- RDAC为75.3% vs 57.7%(P=0.001)。
- OAC为57.7% vs 45.9%(P=0.021)。
- 117例中76.1%(95%CI 69.0-100.0%)坚持换药6个月。
关键数值与推荐
- 坚持换药定义为换用后接受≥1次pMDI且无DPI。
- RDAC定义:无哮喘相关住院、无上呼吸道诊断的抗生素使用、无急性口服激素疗程。
- OAC定义:达到RDAC且沙丁胺醇日均≤200μg或特布他林日均≤500μg。
临床怎么用
- 对使用ICS/LABA的哮喘患者,可考虑将预防性DPI转换为pMDI以改善结局。
- 转换后应关注坚持性,多数患者可维持6个月以上。
局限性
- 单中心历史性队列研究,样本量较小。
- 有效性分析仅纳入坚持换药1年的85例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Mixed inhaler device use for asthma is associated with worse inhaler technique and outcomes. Given that relievers are commonly prescribed as pressurized metred-dose inhalers (pMDI), changing preventers from dry powder inhalers (DPI) to pMDI may improve asthma outcomes. This study aimed to assess the persistence and effectiveness of switching from DPI to pMDI for inhaled corticosteroid and long-acting β2 -agonist combination therapy (ICS/LABA). METHODS: This was a historical cohort study using Ajou University Hospital (Korea) patient records. Persistence of switch was defined as receiving ≥1 pMDI and no DPI after the switch. Effectiveness of switch was assessed as the proportion without severe asthma exacerbation and the proportion achieving risk domain asthma control (RDAC; no asthma-related hospitalization, antibiotics without upper respiratory diagnosis or acute course of oral corticosteroids) and overall asthma control (OAC; RDAC and ≤ 200 μg salbutamol/≤500 μg terbutaline average daily dose) comparing 1 year after and before the switch. RESULTS: Within 85 patients who switched from DPI to pMDI and persisted for a year, higher proportion were free from asthma exacerbation after the switch (mean difference in proportion = 0.129, 95% CI: 0.038-0.220). Switching to pMDI was also associated with better RDAC (75.3% vs 57.7%, P = 0.001) and OAC (57.7% vs 45.9%, P = 0.021). From the entire 117 patients who switched to fixed-dose combination (FDC)/ICS LABA pMDI, 76.1% (95% CI: 69.0-100.0%) patients persisted in the following 6 months. CONCLUSION: Switching to and persisting with pMDI was associated with decreased asthma exacerbations and improved asthma control. The majority of patients persisted with the switch to pMDI for ICS/LABA treatment.
引用
- Park HS, Yoon D, Lee HY, et al. Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. Respirology. 2019. PMID: 31038269. doi:10.1111/resp.13559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。